The Case for Psychedelic Therapy Is Getting Stronger

The Trend: Psychedelic-assisted therapy has been building momentum in research circles for a while now, and a new study published in Nature Medicine is adding to the case. Researchers gave participants with moderate-to-severe depression a single intravenous dose of DMT — the psychoactive compound found in ayahuasca — alongside psychotherapy support. Two weeks later, the DMT group showed a significantly greater reduction in depressive symptoms than the placebo group, with effects holding up for around three months. 

What People Are Saying: The trial was small (34 people), but the results were considered promising enough to warrant more investigation. Researchers are optimistic about medicinal uses for DMT partly because sessions are short — about 30 minutes — compared to psilocybin or MDMA, which can run several hours. The science on psilocybin is also stacking up, with Johns Hopkins reporting antidepressant effects lasting up to a year in some patients. The FDA already approved Spravato, a ketamine-based nasal spray, for treatment-resistant depression back in 2019, and MDMA and psilocybin trials are still in progress. However, therapy is a non-negotiable part of the model for all these treatments. 

What to Know: Access to these cutting-edge treatments are still limited to clinical trial settings. But if standard antidepressants haven’t worked for you, this is a space worth keeping an eye on.